Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for Generics. I cover: How to find and evaluate generic entry…
This article not subject to U.S. Copyright. Published 2019 by the American Chemical Society. Noel T. Southall Abstract We report our experience working with the US Food and Drug Administration…
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th Portfolio Management & Pipeline Optimization for Generics on September 30th.…
This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain patent-term extensions for drugs, pesticides or agricultural chemicals, a careful…
Don’t wait until the end of the year to start looking for alternatives to your existing business intelligence providers. DrugPatentWatch can help you replace or supplement your current solutions with:…
Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at Bentley University published a paper investigating the involvement of government…
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means fewer generic entrants and less opportunities for consumers to enjoy…
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today under a Creative Commons…
This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal of Pharmaceutical Research and Development. 2020; 8(4): 194-212 under an…
When drug patents expire, billions of dollars in revenues can disappear overnight as competitors enter the market. Accordingly, many investors focus on drug patents when evaluating drug companies. But, there…
